GlassScriptPhysician profile
Cortney Fanning
NPI 1265917918
$2,380.56
in general payments reported to CMS, 2019-2025
22 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.28 · 2022: $165 · 2023: $305 · 2024: $1,605 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156 · Travel and Lodging: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.56 |
| Travel and Lodging | $994.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,294.10 | 2024 | |
| Abbvie INC. | $243.79 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $127.43 | 2022-2025 | Rexulti |
| Sanofi Pasteur INC. | $90.74 | 2021-2023 | |
| Amgen INC. | $77.47 | 2023-2025 | Krystexxa, Otezla, Repatha |
| Glaxosmithkline, LLC. | $55.32 | 2023-2024 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $52.55 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $47.50 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $46.17 | 2022-2024 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.68 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $36.53 | 2024-2025 | Veozah |
| Dexcom, INC. | $33.82 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $33.10 | 2024-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $31.06 | 2022 | |
| Organon LLC | $29.65 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.88 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $25.34 | 2025 | Vpriv |
| Neuronetics, INC. | $20.88 | 2025 | Neurostar Tms Therapy System |
| Lundbeck LLC | $20.24 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $17.23 | 2025 | |
| Axsome Therapeutics, INC. | $16.50 | 2024 | Auvelity |
| Lilly USA, LLC | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortney Fanning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.